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Quality of lifeAbstract Electrochemotherapy is an effective and safe method for local treatment of cuta-
neous and subcutaneous tumours, where electric pulses cause increased permeability of cell
membranes in the tumour mass, enabling dramatically enhanced effectiveness of bleomycin
and other hydrophilic drugs. Here, we report results of a European multi-institutional pro-
spective study of the effectiveness of electrochemotherapy in the treatment of skin cancer of
the head and neck (HN) area, where standard treatments had either failed or were not deemed
suitable or declined by the patient. A total of 105 patients affected by primary or recurrent
skin cancer of the HN area were enrolled; of these, 99 were eligible for evaluation of tumour
response. By far, the majority (82%) were treated only once, and 18% of patients had a second
treatment. The objective response was highest for basal cell carcinoma (97%) and for other
histologies was 74%. Small, primary, and treatment-naive carcinomas responded significantly
better (p < 0.05), as investigated by univariate analysis. Electrochemotherapy was well toler-
ated and led to a significant improvement of quality of life, estimated by the European Orga-
nisation for Research and Treatment of Cancer quality of life questionnaires. At 1-year
follow-up, the percentages of overall and disease-free survival were 76% and 89%, respectively.
Electrochemotherapy is an effective option for skin cancers of the HN area and can be consid-
ered a feasible alternative to standard treatments when such an alternative is appropriate. The
precise role for electrochemotherapy in the treatment algorithm for non-melanoma skin cancer
of the HN region requires data from future randomised controlled studies.
(ISRCTN registry N. 30427)
ª 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recurrent or locally advanced neoplasms of the head
and neck (HN) area can be a considerable challenge for
clinicians and debilitating for the patient, especially
when important anatomical structures are involved.
Electrochemotherapy is a relatively new local ablative
technique that utilises electroporation for enhanced
drug (bleomycin or cisplatin) delivery to cells by
generating transient permeation structures in the cell
membrane [1e4]. Over the past 20 years, electro-
chemotherapy has been shown to have proved effec-
tiveness in the treatment of cutaneous, subcutaneous,
mucosal, or deep seated tumours of various histologies
and in different body sites. It is also effective in con-
trolling of bleeding from metastatic tumour deposits and
mass-related symptoms [5e12]. Standard operating
procedures for tumour management with electro-
chemotherapy were published in 2006 [13].
The main advantages of electrochemotherapy are
high local tumour control with minimal damage to
normal tissue, limited side-effects, and good cost/benefit
ratio [10]. The objective response (OR) rate of skin tu-
mours is achieved in 70e80% with good cosmetic results
[12,14]. Recently, interest has increased for its use in
treatment of the tumours in the HN area where specific
clinical problems may arise due to failure or expected
disfigurement of standard treatments. Clinical reports
are now beginning to emerge describing electro-
chemotherapy in treatment of HN tumours [15e18].With the aim of evaluating the acceptability and
effectiveness of electrochemotherapy in treatment of
cutaneous and mucosal cancer of HN area, a European
multi-institutional co-operation was developed for the
European Research on Electrochemotherapy in Head
and Neck Cancer (EURECA) trial. We now report
outcome data for electrochemotherapy treatment for
cutaneous tumours in the HN area.2. Patients and methods
Patients were enrolled and treated at six European in-
stitutions (Pavia, Ljubljana, Barcelona, Bradford,
Amsterdam, and Copenhagen) participating in the
EURECA project and working as part of the Interna-
tional Network for Sharing Practice in Electro-
chemotherapy (INSPECT) Network database (ISRCTN
registry N. 30427). This European multi-institutional
observational prospective longitudinal study was
designed to evaluate the efficacy of electrochemotherapy
in local tumour control as primary outcome measure.
Secondary outcome measures were safety, overall and
disease-free survival (DFS), and the quality of life for
cancer patients with tumours in HN area. Each
participating institution obtained institutional and/or
ethical approval for the study with their respective
bodies. Participating centres uploaded patient de-
mographics, type of tumour, size and site of the target
nodule (in case of multiple nodules of the largest one),
previous treatments information, treatment sessions (no
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tion of pain and quality of life, and follow-up data to the
INSPECT database.
Eligible patients for the study were all patients
affected by recurrent, metastatic, or primary cancer of
the HN area not suitable for surgery or chemo/radio-
therapy because of patient co-morbidity, anticipated
negative outcome of major surgical intervention (high
risk of major intra-postoperative complications, func-
tional sequelae or poor cosmetic result, risk of pro-
longed anaesthesia, etc.), previous treatments or patient
preference. The study also included patients with pri-
mary tumours who refused any other standard treat-
ment. The treatment decision was taken at the level of a
multidisciplinary board after thorough consultation
which included surgeon, radiation and medical oncolo-
gist and the patient. Detailed inclusion and exclusion
criteria are listed in Table 1.2.1. Pre-operative evaluation
Selection of the target nodule was performed according
to the RECIST criteria (version 1.1). The minimum
tumour size for the application of electrochemotherapy
was 1 cm in the longest diameter measured by caliper on
clinical examination or by computed tomography/Table 1
Inclusion and exclusion criteria for the application of
electrochemotherapy.
Inclusion criteria Exclusion criteria
1. Histologically verified
cancer of any type
2. Progressive and/or
metastatic disease
3. Primary disease not eligible
for surgery for patient’s general
conditions or for the need of
extensive surgery
4. Patients must have been
offered standard treatments
5. Measurable lesions suitable
for application of electric pulses
6. Age > 18 years
7. Performance status
(Karnofsky 70; WHO 2)
8. Life expectancy >3 months
9. Treatment free interval of
at least 4 weeks after previously
applied chemo- or radiotherapy
to the target lesions
10. Patients must be mentally
capable of understanding
the information
given and sign informed
consent
1. Other symptomatic
lesions not under control
2. Lesions not suitable for
electrochemotherapy
(bone invasion, large
vessels infiltration, etc.)
3. Acute lung infection
4. Symptoms of poor lung
function necessitates
DLCO and patient
cannot be treated
if this is abnormal
5. Severe coagulation
disorders not
correctable
6. Previous allergic
reactions to bleomycin
7. If cumulative dose
of 240,000 IU BLM/m2
was previously exceeded
8. Chronic renal
dysfunction
(creatinine> 150 mmol/L)
9. Pregnancy or lactation
WHO Z World Health Organisation.magnetic resonance imaging. All nodules were photo-
graphically documented.
Pain intensity was evaluated using the Numeric
Rating Scale (NRS) for pain [19]. NRS is a unidimen-
sional 11-point numeric scale between ‘0’ as ‘no pain’
and ‘10’ as ‘worst pain’. We used a previously published
cutoff on NRS score [20]: 0e2 mild pain, 3e4 moderate
pain, and 5e10 severe pain. Pain medication was
registered as ‘none’, ‘sometimes’, ‘controlled by non-
opioids’, ‘controlled by opioids’, ‘uncontrolled’, or
‘unknown’.
Quality of life (QoL) was evaluated with three QoL
questionnaires (EQ-5D, European Organisation for
Research and Treatment of Cancer [EORTC] QLQ-
C30, and EORTC QLQ-H&N35) [21e23].
2.2. Procedure
Electrochemotherapy was performed according to the
standard operating procedures published in 2006 [13].
Bleomycin was administrated either intravenously (i.v.)
or intratumourally (i.t.), depending on the site, size,
number of skin nodules, and risk of pulmonary fibrosis.
Local anaesthesia (in some centres with sedation) was
generally used for treatment of <3 nodules, <2 cm in
diameter located on the head or face, while general
anaesthesia was preferred in cases with more than three
nodules or when tumours were larger than 2 cm, or
located on the lip, chin, cheek or neck. Electric pulses
(eight pulses of 100 ms duration, amplitude of 1000 V/cm
for needle electrodes or 1300 V/cm for plate electrodes)
were delivered with an electroporator (IGEA srl, Carpi,
Italy) immediately after the i.t. injection or 8 min after
the i.v. injection of bleomycin. The type of the electrode
(plate, row-needle, hexagonal or finger) (IGEA srl) was
chosen according to site, size and shape of the nodule.
2.3. Postoperative evaluation
NRS for pain and QoL questionnaires were collected
every day during inpatient stay and at each follow-up
visit, respectively.
The first two follow-up visits were planned at 1 and 2
months after electrochemotherapy. The cutoff point for
tumour response evaluation was fixed at 2 months.
Tumour response of target lesions was made according
to the RECIST criteria (version 1.1). Biopsies for veri-
fication of tumour response were performed only in case
of unclear clinical and/or radiological evidences.
At each visit, patients were submitted to the same
examinations as during pre-operative evaluation (clin-
ical and radiological, photographic, QoL question-
naires). Adverse events and side-effects were rated
according to the CTCAE, version 4.02.
In cases with partial response (PR) at 2 months
follow-up, a second electrochemotherapy treatment was
considered. In cases with stable disease (SD) or
Table 2
Patient demography and treatment choices.
Pre-treatment visit (105 patients) N %
Gender
- Male 75 71
- Female 30 29
Age (years)
- Median 77
- Range 39e96
- <70 26 25
- 70e80 41 39
- >80 38 36
Diagnosis
BCC 34 32
SCC 50 48
MM 10 9
Other 11 11
Primary disease
- Stage IeII 43 81
- Stage IIIeIV 10 19
Recurrent/metastatic disease
- Stage IeII 45 87
- Stage IIIeIV 7 13
Previous treatments
- Surgery only 33 31
- CT/RT 10 9
- Surgery þ CT/RT 32 31
- No treatment 28 27
- Unknown 2 2
Bleomycin administration
- Local 8 8
- Systemic 97 92
Anaesthesia
- Local 46 44
- General 59 56
Electrodes used
- Plate 4 4
- Row needle 46 44
- Hexagonal 51 49
- Combination 4 4
BCCZ basal cell carcinoma; CTZ chemotherapy; MMZ malignant
melanoma; RT Z radiotherapy; SCC Z squamous cell carcinoma.
Table 3
Size of the treated nodules according to the different histologies.
Histology 3 cm >3 cm Total (%)
BCC 31 3 34 (32)
SCC 26 24 50 (48)
MM 8 2 10 (9)
Other 4 7 11 (11)
Total 69 (66%) 36 (34%) 105 (100)
BCC Z basal cell carcinoma; MM Z malignant melanoma;
SCC Z squamous cell carcinoma.
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the second electrochemotherapy, other treatment op-
tions were considered and applied.
All complete responders were followed up at 4, 8, and
12 months after the treatment. At each follow-up visit,
the same examinations as applied in pre-operative
evaluation were performed.
2.4. Statistics
SPSS (15.0; Statistical Packages for Social Sciences,
Chicago, IL, USA) was used for statistical analysis. In
descriptive analysis, categoric variables have been re-
ported as absolute frequency numbers and percentages;
continuous variables have been reported in terms of
median value and range (minimumemaximum).
Response to treatment was analysed in terms of rate and
compared among groups by the chi-square test. In
follow-up analysis versus baseline, Wilcoxon paired
rank test of sign was used for ordinal data and McNe-
mar’s test for nominal data. Analysis of variance test for
repeated measurements was used to test the hypothesis
controlling for influence of covariates. For survival
analysis, KaplaneMeier analysis was applied. This
analysis was also used to determine 1-year survival,
together with 95% confidence interval. Local DFS was
calculated among patients who reached a complete
response (CR), and progression was defined as appear-
ance of new nodules/recurrences in the treated area. The
analysis of local DFS was performed also on the whole
population, by adapting the survival data on CR pa-
tients with the percentage of CR in the whole
population.
3. Results
3.1. Patients
Between November 2011 and January 2015, 105 patients
with tumours of the skin in the HN area were consec-
utively included. Patient demography is listed in Table 2.
3.2. Tumour histology
According to the protocol, only one target lesion was
taken into consideration for the evaluation of tumour
response to electrochemotherapy (Table 3). Among the
105 electrochemotherapy treated nodules, 50 were
squamous cell carcinoma (SCC), followed by 34 basal
cell carcinoma (BCC), 10 melanoma metastases, and 11
nodules of other histology (3 undifferentiated carci-
noma, 3 adenocarcinoma, 1 renal carcinoma, 1 leio-
myosarcoma, 1 lentigo maligna, 1 syringoma, and 1
sarcomatous tumour). Fig. 1 illustrates the distribution
of the tumour nodules according to anatomical subsites.
Tumours were segregated into smaller and larger
than 3 cm in diameter (overall the tumours ranged from0.2 to 14.5 cm; median 2 cm), the larger lesions
comprising 34% of all the treated nodules (Table 3).
All target tumours were submitted to an initial elec-
trochemotherapy session, while 19 (18%) were re-treated
with a second electrochemotherapy session after a me-
dian time of 114 d (range 21e280 d), to treat residual
tumour (Table 4).
Fig. 1. Distribution of the tumour nodules according to the
different anatomical subsites.
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outcome analysis because the required follow-up of 60 d
was not possible. Four had died due to systemic pro-
gression of the disease not related to the procedure, one
was lost to follow-up, and one patient suffered a serious
adverse event (sepsis-related death post-treatment; see
below). Ninety-nine patients (94%) were finally eligible
for evaluation of tumour response.
3.3. Tumour response
The highest response rate was observed with BCC
(Table 5). Tumours were 20 primary and 14 recurrent
BCC. Thirty-three of 34 (97%) BCC responded with
OR, and of these 91% were CR (Figs 2 and 3). The
treatment was successful also in two of the three tu-
mours that were larger than 3 cm. The only patient with
SD had extensive recurrent lesion of the left orbit and
was not re-treated. Of the two partial responders, one
was re-treated with further PR, and the other was not re-
treated but showed regression of the lesion over the
time.
Overall, 48 (74%) of the 65 other tumour types
showed a response to treatment. Among these, 48%
were CR, 26% PR, and 19% were SD, 4 (6%) PD, and 1
(1%) was not evaluable (NA) due to crust formation and
ulceration at the cutoff point of 2 months (Table 5).
Among this group of other histological tumour types,
the higher percentages of OR were observed for SCC
(Figs 4 and 5) and MM (79% and 77%, respectively).
Univariate analysis of factors influencing tumour
response revealed that it was independent of the
different methods of bleomycin administration, while
tumour characteristics and previous treatments showed
significant correlations, as reported in detail here below.
Tumour size in all the tumours (BCC and all other
histologies) significantly affected the response to elec-
trochemotherapy, i.e. smaller tumours had a higher
response rate (chi-square test p Z 0.0299). In more
detail, tumours 3 cm in diameter showed OR of 88%,
whereas for tumours >3 cm in diameter OR was 68%.Primary tumours responded better than secondary
(recurrent/metastatic) tumours (chi-square test
p Z 0.0330). In fact, for the 50 primary tumours, the
percentage of CR was 70%, PR 20%, SD 8%, and PD
2%. In 49 secondary tumours, the percentage for CR
was 55%, PR 18.5%, SD 18.5%, and PD 6%, and 2% of
treated tumours were not evaluable for response.
Tumours which were not treatment naive showed
reduced effectiveness of electrochemotherapy (no treat-
ment versus previous treatments, chi-square test
p Z 0.0269). Interestingly, for recurrent tumour nod-
ules, previous surgery least affected the outcome
compared to (chemo) radiotherapy or multiple treat-
ments. Among the 49 patients with secondary tumours,
23 had received only surgery as previous treatment,
while 21 had received surgery plus radiotherapy or
chemotherapy (or both) and four had received radio-
therapy or chemotherapy (or both). For one patient,
previous treatments were not reported. The response of
these tumours in patients previously treated with surgery
was 78% CR, 9% PR, and 13% SD. In patients receiving
surgery plus chemotherapy or radiotherapy, 43% had
CR, 24% PR, 19% SD, 9% PD, and 5% NA. Finally,
among the four patients receiving only chemotherapy or
radiotherapy, we observed 1 CR (25%), 2 PR (50%), and
1 PD (25%). The trend from CR in patients previously
treated with surgery shifted towards PR with chemo-
therapy and/or radiotherapy and analysis with the chi-
square test demonstrated a significant difference in
outcome among these groups (surgery only versus other
treatments [p Z 0.0394]).
3.4. Safety of the procedure and side-effects
Crust formation over the treatment was considered part
of the healing process. Minor side-effects included:
actual skin ulceration (14 patients, 5 of grade III), skin
hyperpigmentation (7 patients, grade I/II), suppuration
(4 patients, grade I/II), headache (1 patient, grade I),
nausea (1 patient, grade II), skin odour (2 patients,
grade I/II), dysphagia (1 patient, grade II), and mac-
ulopapular rash (1 patient, grade II).
There was only one major adverse event. A patient
with a large ulcerated tumour died with symptoms
attributable to septic shock on the second day after the
procedure, despite the intra- and postoperative antibi-
otic administration and best supportive care.
In cases of extensive full thickness lesions of cheek,
chin and lips, we observed massive tumour necrosis with
the appearance of loss of oral competence and salivary
fistula formation (four patients). In these cases, no sur-
gical intervention was performed due to the advanced
and local PD; only local medications, feeding tubes or
percutaneous endoscopic gastrostomy (PEG) were used
when necessary.
Moreover, recurrent lesions of the scalp with bone
exposure did not undergo, even in case of CR, closure of
Table 4
Sessions of electrochemotherapy.
Sessions N. (%) Primary Recurrence 3 cm >3 cm
I Electrochemo
therapy
86 (82%) 43 43 53 33
II Electrochemo
therapies
19 (18%) 10 9 16 3
Total 105 (100%) 53 52 69 36
Table 5
Response of skin cancer evaluated at 2 months follow-up.
Response/histology No. of lesions (%) 3 cm >3 cm
BCC
CR 31/34 (91%) 29/34 (85%) 2/34 (6%)
PR 2/34 (6%) 2/34 (6%) 0/34 (0%)
SD 1/34 (3%) 0/34 (0%) 1/34 (3%)
PD 0/34 (0%) 0/34 (0%) 0/34 (0%)
NA 0/34 (0%) 0/34 (0%) 0/34 (0%)
Subtotal 34/34 (100%) 31/34 (91%) 3/34 (9%)
SCC
CR 26/47 (55%) 20/47 (43%) 6/47 (12%)
PR 11/47 (24%) 2/47 (4%) 9/47 (20%)
SD 7/47 (15%) 4/47 (8%) 3/47 (7%)
PD 2/47 (4%) 0/47 (0%) 2/47 (4%)
NA 1/47 (2%) 0/47 (0%) 1/47 (2%)
Subtotal 47/47 (100%) 26/47 (55%) 21/47 (45%)
MM
CR 5/9 (55%) 4/9 (44%) 1/9 (11%)
PR 2/9 (22%) 2/9 (22%) 0/9 (0%)
SD 1/9 (11%) 1/9 (11%) 0/9 (0%)
PD 1/9 (11%) 0/9 (0%) 1/9 (11%)
NA 0/9 (0%) 0/9 (0%) 0/9 (0%)
Subtotal 9/9 (100%) 7/9 (78%) 2/9 (22%)
Other
CR 0/9 (0%) 0/9 (0%) 0/9 (0%)
PR 4/9 (44%) 1/9 (11%) 3/9 (33%)
SD 4/9 (44%) 3/9 (33%) 1/9 (11%)
PD 1/9 (11%) 0/9 (0%) 1/9 (11%)
NA 0/9 (0%) 0/9 (0%) 0/9 (0%)
Subtotal 9/9 (100%) 4/9 (44%) 5/9 (56%)
Total 99/99 (100%) 68/99 (69%) 31/99 (31%)
BCC Z basal cell carcinoma; CR Z complete response;
MM Z malignant melanoma; NA Z not available for crusts or ul-
ceration; Other Z other skin malignancies; PR Z partial response;
PD Z progressive disease; SCC Z squamous cell carcinoma;
SD Z stable disease.
3 cmZ maximum diameter of the target lesion less or equal to 3 cm;
>3 cm Z maximum diameter of the target lesion greater than 3 cm.
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healed well with no or only minor tissue defects.
3.5. Pain
Electrochemotherapy did not significantly affect pain
levels in patients with no or only mild pain reported
before the treatment. It did not relieve pain in patients
with pain before treatment. However, during follow-up,
the percentage of patients with no pain significantly
increased (70e90% at 3 months), and incidence of severe
pain significantly decreased (19e3% at 3 months).
Univariate analysis of factors influencing the post-
operative pain score revealed that pain in the first month
after treatment was significantly higher in patients with
larger lesion size (p < 0.0001), lesions in previously
irradiated areas (p Z 0.0005), and SCC (p Z 0.009).
The percentage of patients not taking pain medica-
tion (70% before treatment) increased after treatment up
to 82% at 3 months after electrochemotherapy, and it is
noteworthy that only few patients took opioids at
baseline (11%), falling to 2% after treatment.
3.6. Quality of life
The analysis of QoL showed a significant progressive
positive perception of well-being for the EQ-5D (Fig. 6),
a significant improvement of physical functioning, role
functioning and decrease of fatigue and pain for QLQ-
C30 (Fig. 7). There was a general improvement in all
domains of the QLQ-H&N35, with perception of feeling
ill, pain and use of analgesics, and mouth opening being
the most significant (Fig. 8).
3.7. Survival
During 1-year follow-up (median 6 months; range 15
d e 12 months), 10 of the 62 patients with CR (16%) had
a recurrence in the treated area after a mean period of
8.3  3.5 months (median 8.1, range 2.6e13.6) after the
first electrochemotherapy. Of these, four were BCC and
six were SCC. The dimensions of the original lesions in
these cases were 25, 10, 8, and 5 mm and 50, 24, 17, 15,
15, and 7 mm, respectively.
Further analysis of these ten patients showed that
four were treated only once and then went off study;
three patients had already received two cycles of elec-
trochemotherapy when they had recurrences and wentoff study for other treatments and three patients were
retreated immediately after recurrence (two of these had
CR, the last went off study because unwilling to follow-
up).
KaplaneMeier overall survival curves for the whole
group of patients and for the different histologies are
shown in Figs. 8 and 9. At 12 months of follow-up, the
overall survival rate was 76% (confidence interval [CI]
66e85%). All BCC patients survived during the follow-
up period, survival rate at 12 months for SCC patients
was 64% (CI 49e78%); for MM 89% (CI 68e100%) and
for the other histologies 46% (CI 4e88%).
Analysis of the 1-year local DFS made on the whole
cohort of patients as well as for the subgroup of patients
with CR and for their different histologies are illustrated
in Figs. 10 and 11. Among CR patients, we observed an
overall DFS of 89% (CI 69e97%) with the following
differences for the different histologies: MM 100% (only
four cases reached 1-year follow-up), BCC 89% (CI
75e100%), and SCC 87% (CI 72e100%).
Fig. 2. Primary BCC: baseline (left), 2 months after ECT (center), and 1 year after ECT (right) (finger electrode 10 mm, local anaesthesia,
i.v. bleomycin 15,000 IU/m2, 3 pulses). The patient was offered surgery and radiotherapy but refused both due to respectively cosmetical
and functional outcome (surgery), and long duration treatment (radiotherapy). The patient explained that he would prefer to try ECT
reserving surgery or radiotherapy for possible recurrence.
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This study describes the largest clinical trial of mela-
noma and non-melanoma skin cancers of the HN area
treated with bleomycin electrochemotherapy. This mo-
dality is shown to be effective with OR rates in accor-
dance with previous papers ranging from 59% to 100%
[15,17,18]. The response rates here reported must be
seen in the light of this study reporting results of elec-
trochemotherapy in patients with tumours recurrent
after other treatments (71%) and also with a high per-
centage of tumours over 3 cm in diameter (34%). In
addition, 1-year overall survival and local DFS rates
(76% and 89%, respectively) were favourable, further
confirming the effectiveness of this treatment in skin
tumours of the HN area. We also demonstrate for the
first time that quality of life was improved after elec-
trochemotherapy with long-lasting positive effects on
pain control, perception of well-being, physical func-
tioning, and role functioning, as demonstrated by the
results of the three QoL questionnaires.
The success of this treatment was dependent on
tumour type and was most effective in BCC, in agree-
ment with other studies [5,15,24e26]. Our findings also
suggest that the use of electrochemotherapy should be as
early as possible in disease progression in selected cases,
such as the elderly or patients with multifocal disease to
avoid disfiguring treatment outcomes.
Unfortunately, our data do not provide information
about tumour response with different subtypes of BCC
(nodular versus morphemic) due to histopathological
details not being recorded. Our data suggest that a
margin of normal-appearing tissue surrounding the
lesion of at least 5e10 mm, adapted to the shape and
size of the lesion, must be treated to maximise tumour
response. This is similar to guidelines for surgical
treatment and radiotherapy planning [27].The high response rates seen in this study appears to
be influenced by several factors, which should be taken
into consideration when deciding on the best treatment
option for individual patient.
The response to electrochemotherapy is significantly
correlated with tumour size, as has previously been
demonstrated [10]. These studies demonstrated that
electrochemotherapy is more effective in small tumour
nodules (<3 cm) and in sarcoma compared with carci-
noma tumour nodules. This previous work could not
evaluate differences in time to response by differing
tumour types and this is a novel finding in our work.
Response rate was also dependent on previous
treatment. The most responsive cases were treatment-
naive patients with primary tumours, whereas previous
chemotherapy and/or (chemo)radiotherapy significantly
decreased tumour response rate. These data lead us to
similar conclusions to those of Campana et al. [18] in a
retrospective series of non-melanoma HN cancers.
These investigators stated that chemotherapy resistance
and changes in tissue produced by previous treatments,
such as disruption of the vasculature, scarring or ne-
crosis, can impair blood supply thus impairing drug
distribution.
This study has also confirmed that electro-
chemotherapy is in general a safe procedure, with only
minimal side-effects, in line with previous reports [8,17].
Regarding the ulceration and healing time, an
important issue is dose of the drug. In some earlier
studies [2], an i.t. dose of bleomycin 5 times larger than
the one used in the current study (which results from the
Standard operating procedures [SOP] of the ESOPE
study [13]) and a voltage of 1.3 kV/cm were used,
whereas in the current study, in accordance with the
SOP published from the ESOPE group [13], only 1 kV/
cm was used for the needle electrodes. The higher dose
of bleomycin (fivefold greater), combined with almost
Fig. 3. Recurrent BCC: baseline (left), 2 months after ECT (center), 1 year after ECT (right) (row-needle electrode 10 mm; local
anaesthesia þ sedation; i.v. bleomycin 15,000 IU/m2, 4 pulses) The patient was previously submitted to surgery (three times) and refused
another operation. Radiotherapy was deemed less optimal due to extension over both the nose, cheek, and up to the medial cantus
(arrow).
Fig. 4. Primary SCC in a patient with concomitant lung metastases from colorectal carcinoma: baseline (left), 2 months after ECT (center),
and 7 months after ECT (right) (exagonal electrode 30 mm, general anaesthesia, i.v. bleomycin 15,000 IU/m2, 6 pulses). Due to advanced
stage of the patients colorectal carcinoma, life expectancy was limited and major surgery was deemed to be an unreasonable intervention
for this patient, likewise a long treatment course of radiotherapy was discouraged. At the same time, the patient had symptoms and so a
short intervention as ECT was chosen.
Fig. 5. Recurrent SCC: baseline (left), 2 months after ECT (center), 1 year after ECT (right) (exagonal electrode 10 mm, general
anaesthesia, i.v. bleomycin 15000 IU/m2, 3 pulses) The patient was previously submitted to partial maxillectomy and refused another
major operation with reconstruction. Furthermore, the patient suffered from rapidly progressing Parkinson’s disease. Radiotherapy was
suggested, but refused by the patient due to the long duration of treatment. Thus he preferred to try ECT.
Fig 6. EQ-5D mean values at baseline and at each follow-up visit.
G. Bertino et al. / European Journal of Cancer 63 (2016) 41e524830% increase in voltage have been shown to produce a
much higher risk of ulceration. Following the SOP [13]
has in this and other studies resulted in a low level of
normal tissue damage. In this study, 92% of patients
received chemotherapy i.v. and only 8% had drug
injected directly i.t; i.t. injection was used only where
patients had documented chronic obstructive pulmo-
nary disease at risk for pulmonary fibrosis [28].
In cases with extensive, necrotic skin lesions, we
consider it mandatory to administer perioperative sys-
temic antibiotic therapy in order to reduce the risk of
sepsis due to systemic release of bacteria and bacterial
products from the microflora colonising the tumour
Fig. 7. QLQ-C30 mean values at baseline and at each follow-up visit.
G. Bertino et al. / European Journal of Cancer 63 (2016) 41e52 49nodule, as happened in one case in this trial. Further, in
patients with lesions infiltrating full thickness of skin
coverage on the cheek, chin or lips, wide loss of tissue
with fistula formation or labial incompetence must be
anticipated and considered in the pre-treatment decision
process. Patients must then be thoroughly informed of
these potential complications, which will negatively
impact quality of life if reconstruction is not possible.
Our data on pain confirmed the findings recently
published by the INSPECT group [29]. In general,
electrochemotherapy does not result in increased pain
immediately after treatment and this was observed both
for patients with pre-existing none or mild pain and for
patients with pre-existing severe pain. However, pain
was usually observed to increase in the following 45 d
after treatment and then decrease [29].
Of note also is that electrochemotherapy did not
require increased dosage of drugs for pain relief and the
percentage of patients taking opioids, although low
before treatment, significantly dropped after, in agree-
ment with the findings of Quaglino et al. [29] who
demonstrated that patients need significantly less anal-
gesic medication after treatment. Analysis of factors
influencing the baseline pain score and the level of pain
after treatment revealed that the most significant de-
terminants were tumour size, previous treatments and
SCC histology. Once again, this evidence is consistent
with Quaglino et al. [29] who hypothesised that largelesions or pre-treated areas, especially pre-irradiated
ones, can lead to a more severe tumour necrosis and
inflammation, resulting in more severe pain. Taking this
information into account, it is possible to identify a spe-
cific population of patients who may be at risk of severe
pain after electrochemotherapy and, therefore, are can-
didates for specific pain-relief treatment protocols.
Interestingly, quality of life improved after ECT with
long-lasting positive effects on pain control, perception
of well-being, physical functioning and role functioning,
as demonstrated by the results of the three QoL ques-
tionnaires in our study.
This is the first prospectively designed study focused
on HN non-melanoma skin cancer that has evaluated
overall and local DFS of patients submitted to electro-
chemotherapy. The observed 12-month overall survival
and DFS rates of 76% and 89%, respectively, are high,
even in view of rather short follow-up time (median 6
months).
Furthermore, in this study histologic confirmation of
treatment response was not an end-point, although the
biopsy was performed upon clinical suspicion of either
remaining tumour or recurrence.
The purpose of this study has been to investigate
ECT as an option in patients where standard treatment
modalities have been deemed not indicated due to ex-
pected increase in the risk of serious morbidity or of
unacceptable functional outcome. Further, where
Fig. 8. QLQ-H&N35 mean values at baseline and at each follow-up visit.
G. Bertino et al. / European Journal of Cancer 63 (2016) 41e5250patients declined proposed surgery or radiotherapy, or
where co-morbidities played an important role in
treatment decision-making process. Certainly, the ma-
jority of patients with HN skin cancer can be adequately
treated using dermatological treatments, surgery or
radiotherapy; however, this does not mean that further
alternatives are not necessary. Whether electro-
chemotherapy could play a role in primary treatment of
these cancers requires to be investigated in future
randomised controlled trials.Fig. 9. Overall survival in total cohort and in subgroups per diagno
SCC Z squamous cell carcinoma; OTH Z other histologies.5. Conclusions
Electrochemotherapy is an effective treatment option
for skin tumours of the HN area and in particular for
BCC. The response rate in small, primary, and
treatment-naive tumours is high and the functional,
anatomical, and aesthetic preservation of the HN
structures can be excellent in such cases. Randomised
trials will be needed to evaluate a possible role for
electrochemotherapy as a first-line curative treatment.sis. BCC Z basal cell carcinoma; MM Z malignant melanoma;
Fig. 10. Local disease-free survival in the total cohort and in subgroups per diagnosis. BCC Z basal cell carcinoma; MM Z malignant
melanoma; SCC Z squamous cell carcinoma.
Fig. 11. Local disease-free survival in CR patients observed in the total cohort and in subgroups per diagnosis. BCC Z basal cell car-
cinoma; MM Z malignant melanoma; SCC Z squamous cell carcinoma.
G. Bertino et al. / European Journal of Cancer 63 (2016) 41e52 51Conflict of interest statement
IGEA (Carpi, Italy) hosts the INSPECT database,
but the database is controlled by an independent board,
and the uploaded data are contractually belonging to
the investigators involved. Francesca de Terlizzi is an
IGEA employee. All the authors were invited to meet-
ings on electrochemotherapy by IGEA.
Appendix A. Supplementary data
Supplementary data related to this article can be found
at http://dx.doi.org/10.1016/j.ejca.2016.05.001.References
[1] Mir LM, Orlowski S, Belehradek Jr J, Paoletti C. Electro-
chemotherapy potentiation of antitumour effect of bleomycin by
local electric pulses. Eur J Cancer 1991;27:68e72.[2] Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC,
Gilbert RA, Glass LF. Treatment of cutaneous and subcutaneous
tumours with electrochemotherapy using intralesional bleomycin.
Cancer 1998;83:148e57. http://dx.doi.org/10.1002/(SICI)1097-
0142(19980701)83:1<148::AID-CNCR20>3.0.CO;2-W.
[3] Gehl J, Geertsen PF. Efficient palliation of haemorrhaging ma-
lignant melanoma skin metastases by electrochemotherapy. Mel-
anoma Res 2000;10:585e9.
[4] Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z. Elec-
trochemotherapy with cisplatin: clinical experience in malignant
melanoma patients. Clin Cancer Res 2000;6:863e7.
[5] Glass LF, Jaroszeski M, Gilbert R, Reintgen DS, Heller R.
Intralesional bleomycin-mediated electrochemotherapy in 20 pa-
tients with basal cell carcinoma. J Am Acad Dermatol 1997;37:
596e9.
[6] Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M,
Billard V, Geertsen PF, Larkin JO, Miklavcic D, Pavlovic I,
Paulin-Kosir SM, Cemazar M, Morsli N, Soden DM,
Rudolf Z, Robert C, O’Sullivan GC, Mir LM. Electro-
chemotherapy e an easy, highly effective and safe treatment of
cutaneous and subcutaneous metastases: results of ESOPE
(European Standard Operating Procedures of Electro-
chemotherapy) study. Eur J Cancer Suppl 2006;4:3e13. http:
//dx.doi.org/10.1016/j.ejcsup.2006.08.002.
G. Bertino et al. / European Journal of Cancer 63 (2016) 41e5252[7] Quaglino P, Mortera C, Osella-Abate S, Barberis M, Illengo M,
Rissone M, Savoia P, Bernengo MG. Electrochemotherapy with
intravenous bleomycin in the local treatment of skin melanoma
metastases. Ann Surg Oncol 2008;15:2215e22. http:
//dx.doi.org/10.1245/s10434-008-9976-0.
[8] Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M.
Electrochemotherapy in treatment of tumours. Eur J Surg Oncol
2008;34:232e40. http://dx.doi.org/10.1016/j.ejso.2007.05.016.
[9] Campana LG, Mocellin S, Basso M, Puccetti O, De Salvo GL,
Chiarion-Sileni V, Vecchiato A, Corti L, Rossi CR, Nitti D.
Bleomycin-based electrochemotherapy: clinical outcome from a
single institution’sexperience with 52 patients. Ann Surg Oncol
2009;16:191e9. http://dx.doi.org/10.1245/s10434-008-0204-8.
[10] Matthiessen LW, Chalmers RL, Sainsbury DCG, Veeramani S,
Kessell G, Humphreys AC, Bond JE, Muir T, Gehl J. Manage-
ment of cutaneous metastases using electrochemotherapy. Acta
Oncologica 2011;50:621e9. http://dx.doi.org/10.3109/
0284186X.2011.573626.
[11] Curatolo P, Quaglino P, Marenco F, Mancini M, Tiziana
Nardo` T, Mortera C, Rotunno R, Calvieri S, Bernengo MG.
Electrochemotherapy in the treatment of Kaposi sarcoma
cutaneous lesions: a two-center prospective phase II trial. Ann
Surg Oncol 2012;19:192e8. http://dx.doi.org/10.1245/s10434-
011-1860-7.
[12] Cadossi R, Ronchetti M, Cadossi M. Locally enhanced chemo-
therapy by electroporation: clinical experiences and perspective of
use of electrochemotherapy. Future Oncol 2014;10:877e90. http:
//dx.doi.org/10.2217/fon.13.235.
[13] Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V,
Geertsen PF, Rudolf Z, O’Sullivan GC, Marty M. Standard
operating procedures of the electrochemotherapy: instructions
for the use of bleomycin or cisplatin administered either sys-
temically or locally and electric pulses delivered by the Clin-
iporator (TM) by means of invasive or non-invasive
electrodes. Eur J Cancer Suppl 2006;4:14e25. http:
//dx.doi.org/10.1016/j.ejcsup.2006.08.003.
[14] Spratt DE, Gordon Spratt EA, Wu S, DeRosa A, Lee NY,
Lacouture ME, Barker CA. Efficacy of skin-directed therapy for
cutaneous metastases from advanced cancer: a meta-analysis. J
Clin Oncol 2014;32:3144e55. http://dx.doi.org/10.1200/
JCO.2014.55.4634.
[15] Gargiulo M, Papa A, Capasso P, Moio M, Cubicciotti E,
Parascandolo S. Electrochemotherapy for non-melanoma head
and neck cancers. Clinical outcomes in 25 patients. Ann Surg
2012;255:1158e64. http:
//dx.doi.org/10.1097/SLA.0b013e31824f68b2.
[16] Scelsi D, Mevio N, Bertino G, Occhini A, Brazzelli V, Morbini P,
Benazzo M. Electrochemotherapy as a new therapeutic strategy in
advanced Merkel cell carcinoma of the head and neck region.
Radiol Oncol 2013;47:366e9. http://dx.doi.org/10.2478/raon-
2013-0059.
[17] Mevio N, Bertino G, Occhini A, Scelsi D, Tagliabue M, Mura F,
Benazzo M. Electrochemotherapy for the treatment of recurrent
head and neck cancers: preliminary results. Tumori 2012;98:
308e13. http://dx.doi.org/10.1700/1125.12397.
[18] Campana LG, Mali B, Sersa G, Valpione S, Giorgi CA,
Strojan P, Miklavcic D, Rossi CR. Electrochemotherapy in non-
melanoma head and neck cancers: a retrospective analysis of thetreated cases. Br J Oral Maxillofac Surg 2014;52:957e64. http:
//dx.doi.org/10.1016/j.bjoms.2014.08.004.
[19] Hawker GA, Mian S, Kendzerska T, French M. Measures of
adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric
Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire
(MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ),
Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain
Scale (SF-36 BPS), and Measure of Intermittent and Constant
Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 2011;
63(Suppl. 11):S240e52. http://dx.doi.org/10.1002/acr.20543.
[20] Gerbershagen HJ, Rothaug J, Kalkman CJ, Meissner W. Deter-
mination of moderate-to-severe postoperative pain on the
numeric rating scale: a cut-off point analysis applying four
different methods. Br J Anaesth 2011;107:619e26. http:
//dx.doi.org/10.1093/bja/aer195.
[21] EQ-5D value sets: inventory, comparative review and user guide.
In: Szende A, Oppe M, Devlin N. (Eds.) Euro QoL group
monographs. Springer, Dordrecht (2007), ISBN 978e1402055102
[22] Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D,
Bottomley A, on behalf of the EORTC Quality of Life Group:
The EORTC QLQ-C30 scoring manual, 3rd ed. European
Organisation for Research and Treatment of Cancer (EORTC),
Brussels (2001).
[23] Sherman AC, Simonton S, Adams DC, Vural E, Owens B,
Hanna E. Assessing quality of life in patients with head and neck
cancer: cross-validation of the European Organization for
Research and Treatment of Cancer (EORTC) Quality of Life
Head and Neck module (QLQ-H&N35). Arch Otolaryngol Head
Neck Surg 2000;126:459e67.
[24] Landstro¨m FJ, Nisson CO, Crafoord S, Reizenstein JA,
Adamsson GB, Lo¨fgren LA. Electroporation therapy of skin
cancer in the head and neck area. Dermatol Surg 2010;36:
1245e50. http://dx.doi.org/10.1111/j.1524-4725.2010.01617.x.
[25] Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F,
Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I,
Passoni C, Pari C, Di Pietro A, Ferrucci PF. Electro-
chemotherapy for cutaneous and subcutaneous tumour lesions: a
novel therapeutic approach. Dermatol Ther 2010;23:651e61.
http://dx.doi.org/10.1111/j.1529-8019.2010.01370.x.
[26] Kis E, Balta´s E, Kinyo´ A, Varga E, Nagy N, Gyulai R,
Keme´ny L, Ola´h J. Successful treatment of multiple basaliomas
with bleomycin-base electrochemotherapy: a case series of three
patients with Gorlin-Goltz syndrome. Acta Derm Venereol 2012;
92:648e51. http://dx.doi.org/10.2340/00015555-1361.
[27] Telfer NR, Colver GB, Morton CA. Guidelines for the manage-
ment of basal cell carcinoma. Brit J Dermatol 2008;159:35e48.
http://dx.doi.org/10.1111/j.1365-2133.2008.08666.x.
[28] Grahmann PR, Brauer M, Hu¨ter L, Sayer H, Neumann R,
Braun RK. Respiratory failure and pulmonary fibrosis as late
side-effect after chemotherapy-induced by oxygen administration.
Pneumologie 2005;59:763e9.
[29] Quaglino P, Wichmann Matthiessen L, Curatolo P, Muir T,
Bertino G, Kunte C, Odili J, Rotunno R, Humphreys AC,
Letule´ V, Marenco F, Cuthbert C, Albret R, Benazzo M, De
Terlizzi F, Gehl J. Predicting patients at risk for pain associated
with electrochemotherapy. Acta Oncologica 2015;54:298e306.
http://dx.doi.org/10.3109/0284186X.2014.992546.
